MedPath

First Patient Dosed in Marengo's Invikafusp Alfa Trial Expansion to Europe

7 months ago1 min read
According to GlobalData's 'Clinical Trial Descriptors Trends Insight Report Overview' report, oncology was the largest therapy area within FIH trials as of September 2023. Following oncology, infectious diseases and the central nervous system were also significant areas of focus for some trials. The GlobalData clinical trial database highlights that there are 1,540 ongoing FIH clinical trials in oncology across 3,359 sites at the time of writing.
This expansion of Marengo's invikafusp alfa trial into Europe represents a pivotal moment in the ongoing research and development efforts within the oncology sector. The dosing of the first patient in this expanded trial phase underscores the commitment to advancing therapeutic options for patients battling cancer.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.